Drug study aims to free PNH patients from blood transfusions
NCT ID NCT07036718
Summary
This study observes how well the drug iptacopan works for adults with paroxysmal nocturnal hemoglobinuria (PNH) during routine medical care in Russia. Researchers will follow 100 patients already prescribed iptacopan by their doctors to see if it increases their hemoglobin levels and reduces their need for blood transfusions over 12 months. The goal is to understand the drug's real-world effectiveness and safety for managing this rare blood disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PAROXYSMAL NOCTURNAL HEMOGLOBINURIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
Novartis Investigative Site
RECRUITINGSyktyvkar, Komi, 167904, Russia
-
Novartis Investigative Site
RECRUITINGGrozny, 364047, Russia
-
Novartis Investigative Site
RECRUITINGKrasnodar, 350040, Russia
-
Novartis Investigative Site
RECRUITINGMoscow, 129110, Russia
-
Novartis Investigative Site
RECRUITINGMurmansk, 183047, Russia
-
Novartis Investigative Site
RECRUITINGSaint Petersburg, 194291, Russia
-
Novartis Investigative Site
RECRUITINGSaint Petersburg, 198205, Russia
-
Novartis Investigative Site
RECRUITINGYuzhno-Sakhalinsk, 693000, Russia
Conditions
Explore the condition pages connected to this study.